Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Multispecific antibodies have emerged as versatile therapeutic agents, and therefore,
approaches to optimize and streamline their design and assembly are needed. Here we …

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

The potential roles of breast cancer stem cells (BCSCs) in tumor initiation and recurrence
have been recognized for many decades. Due to their strong capacity for self-renewal and …

The clinical development of 4–1BB agonists for cancer immunotherapy has raised
substantial interest during the past decade. The first generation of 4–1BB agonistic …

Nanotechnology takes the lead in providing new therapeutic options for cancer patients. In
the last decades, lipid-based nanoparticles—solid lipid nanoparticles (SLNs) …

Despite the clinical success of the first bispecific antibody approved by the FDA against B
cell malignancies (blinatumomab), many obstacles remain such as dosing, treatment …

The introduction of immune checkpoint inhibitors has changed the therapeutic possibilities
for various cancer types. However, despite the success in some entities, a significant fraction …

One major limitation of neutralizing antibody-based COVID-19 therapy is the requirement of
costly cocktails to reduce emergence of antibody resistance. Here we engineer two …